Merck anion-dependent farnesyl transferase inhibitor

EB-42486 (ESCAPE Bio oral G2019S-LRRK2 mutant-selective kinase inhibitor)

“compound 4d” (Merck oral selective PI3K delta kinase inhibitor)

“compound 60b” (Taisho D486N mutant RSV fusion protein inhibitor clinical candidate)

“compound 15a” (Novartis reversible in vivo ATX inhibitor)

“compound 31” (Merck cholesteryl ester transfer protein (CETP) inhibitor)

“compound 36” (GlaxoSmithKline (GSK) oral TRPV4 ion channel antagonist backup)

BCPyr (Pfizer cIAP1-based BTK degrader)

“compound 4j” (Janssen (JNJ) brain-penetrant in vivo 5-HT2 antagonist and 5-HT7 inverse agonist, backup candidate)

Chugai/Lilly clinical oral non-peptide GLP-1R GPCR partial agonist

Servier selective clinical Mcl-1 protein-protein interaction (PPI) inhibitor

Bristol-Myers Squibb (BMS) pan-genotype HCV NS3/4A protease inhibitor

MLT-985 (Novartis allosteric MALT1 protease (paracaspase) inhibitor)

Idorsia clinical dual orexin receptor GPCR antagonist

Merck/UCB/Ra Pharma macrocyclic PCSK9 protein-protein interaction (PPI) inhibitor

OATD-01 (OncoArendi Therapeutics oral, first-in-class CHIT1/AMCase chitinase inhibitor clinical candidate)

CC-90011 (Celgene/Bristol Myers Squibb (BMS)) selective, reversible LSD1 inhibitor clinical candidate)

CG428 (Cullgen CRBN-based TRK kinase fusion protein degrader)